Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03353220 · ClinicalTrials.gov registry record · Phase 4
Predictors of Lorcaserin-Induced Weight Loss
A Phase 4 study, sponsored by Columbia University.
- Terminated
- Registry status
- Phase 4
- Development phase
- 32
- Enrollment target
NCT03353220 is a Phase 4 study that was terminated before completion, run by Columbia University. The registered enrollment target is 32 participants.
The verdict
NCT03353220, a Phase 4 study, was terminated before completion, sponsored by Columbia University.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 32 participants
- Enrollment target
Study Summary
This two-phase study aims to explore ways to predict who will respond well to the weight loss drug lorcaserin and to understand the mechanisms that develop which limit drug efficacy. Subjects will be recruited for a 5-week crossover study (phase 1) with lorcaserin and placebo followed by treatment with lorcaserin for 24 weeks (phase 2).
Interventions
- DRUG Placebo
- DRUG Belviq
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2018-01-03 |
| Est. Completion | 2020-02-14 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03353220
The ClinicalTrials.gov registry entry for NCT03353220 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Columbia University, which has 958 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03353220 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03353220 about?
NCT03353220 is a clinical study titled "Predictors of Lorcaserin-Induced Weight Loss". This two-phase study aims to explore ways to predict who will respond well to the weight loss drug lorcaserin and to understand the mechanisms that develop which limit drug efficacy. Subjects will be recruited for a 5-week crossover study (phase 1) with lorcaserin and placebo followed by treatment w...
What is the current status of trial NCT03353220?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 32 participants. The study started on 2018-01-03. Estimated completion is 2020-02-14.
What interventions are being tested in trial NCT03353220?
The interventions under investigation include: Placebo (DRUG), Belviq (DRUG).
Who is sponsoring clinical trial NCT03353220?
This trial is sponsored by Columbia University, which has 958 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.